Syntex (u.s.a.) Inc.

Syntex Pharmaceuticals International Limited

Shabbir T Anik

Eric J Benjamin

Ya-Yun T Lin

Brian H Vickery

Richard E Jones

The present invention relates to a novel nasal composition comprising a nona- or decapeptide having LHRH agonist or antagonist activity and a surfactant which is a bile acid or a pharmaceutically acceptable salt thereof in a buffered aqueous solution.

LHRH preparations for intranasal administration

A non-stinging aqueous anti-inflammatory steroid formulation suitable for intranasal administration comprises: an anti-inflammatory steroid in an amount between about 0.01% and about 0.05% (w/v); propylene glycol in an amount between about 2% and about 10% (w/v); PEG 400 in an amount between about 10% and about 25% (w/v); polysorbate 20 in an amount between about 1% and about 4% (w/v); an effective amount of a preservative; an effective amount of a stabilizer; an effective amount of an antioxidant; water; and pH buffering agent sufficient to adjust the pH of the resulting solution to between about 3.5 and about 7.

Aqueous steroid formulations for nasal administration

Disclosed herein are nasal spray compositions and methods for enhancing polypeptide absorption across nasal membranes comprising a chelating agent and a polypeptide in a pharmaceutically acceptable excipient.

Polypeptides/chelating agent nasal compositions having enhanced peptide

A gel formulation, which is inherently spermicidal and which provides an efficient delivery system for spermicidal and other contraceptively effective compounds intravaginally is disclosed. Said formulation is useful in methods of intravaginal contraception.

Growing community of inventors

Palo Alto, CA, United States of America

Shabbir T Anik